Immunovant, Inc. (IMVT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immunovant, Inc. (IMVT) closed at USD 27.90 on 2026-10-14, a change of +26.9 % over the past year, with a market capitalization of USD 5.68B.

Immunovant, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immunovant, Inc. key figures

Previous close

USD 27.90 (2026-10-14)

1-year change

+26.9 %

Market cap

USD 5.68B

Enterprise value

USD 4.88B

P/E ratio (trailing)

-10.19

P/E ratio (forward)

-10.00

EPS (trailing)

-2.70

EPS (forward)

-2.75

PEG ratio

n/a

Price to book

7.72

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.32

Employees

315

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immunovant, Inc. and compare it with other stocks.